Metformin as a booster or obstacle of immunotherapy in patients with non–small cell lung cancer and diabetes mellitus

CancerEarly View LETTER TO THE EDITOR Metformin as a booster or obstacle of immunotherapy in patients with non–small cell lung cancer and diabetes mellitus This article relates to: Reply to "Metformin as a booster or obstacle of immunotherapy in patients with non–small cell lung cancer and diabetes mellitus" Yasmin Leshem MD, PhD, Yardenna Dolev MD, Nava Siegelmann-Danieli MD, Sarah Sharman Moser MSc, Lior Apter BPharm MSc, Gabriel Chodick PhD, Alla Nikolaevski-Berlin PhD, Sivan Shamai MD, Ofer Merimsky MD, Ido Wolf MD, Cancer First Published online: November 21, 2023 Ming-Cheng Guan MD, Ming-Cheng Guan MD Department of Medical Oncology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, ChinaSearch for more papers by this authorQian Ding MD, Qian Ding MD Department of Medical Oncology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, ChinaSearch for more papers by this authorJing Ning MD, Jing Ning MD Department of Oncology, Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, Jiangsu, ChinaSearch for more papers by this authorHong Zhu MD, PhD, Corresponding Author Hong Zhu MD, PhD [email protected] orcid.org/0000-0001-7502-278X Department of Medical Oncology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China Correspondence Hong Zhu. Email: [email protected]Search for more papers by this author Ming-Cheng Guan MD, Ming-Cheng Guan MD Department of Medical Oncology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, ChinaSearch for more papers by this authorQian Ding MD, Qian Ding MD Department of Medical Oncology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, ChinaSearch for more papers by this authorJing Ning MD, Jing Ning MD Department of Oncology, Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, Jiangsu, ChinaSearch for more papers by this authorHong Zhu MD, PhD, Corresponding Author Hong Zhu MD, PhD [email protected] orcid.org/0000-0001-7502-278X Department of Medical Oncology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China Correspondence Hong Zhu. Email: [email protected]Search for more papers by this author First published: 21 November 2023 https://doi.org/10.1002/cncr.35111Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Leshem Y, Dolev Y, Siegelmann-Danieli N, et al. Association between diabetes mellitus and reduced efficacy of pembrolizumab in non–small cell lung cancer. Cancer. 2023; 129(18): 2789-2797. doi:10.1530/endoabs.90.p379 10.1002/cncr.34918 CASGoogle Scholar 2Chen P, Liu Y, Wen Y, Zhou C. Non–small cell lung cancer in China. Cancer Commun. 2022; 42(10): 937-970. doi:10.1002/cac2.12359 10.1002/cac2.12359 Web of Science®Google Scholar 3Oswalt C, Liu Y, Pang H, Le-Rademacher J, Wang X, Crawford J. Associations between body mass index, weight loss and overall survival in patients with advanced lung cancer. J Cachexia Sarcopenia Muscle. 2022; 13(6): 2650-2660. doi:10.1002/jcsm.13095 10.1002/jcsm.13095 PubMedWeb of Science®Google Scholar 4Chen YM, Lai CH, Lin CY, et al. Body mass index, weight loss, and mortality risk in advanced-stage non–small cell lung cancer patients: a focus on EGFR mutation. Nutrients. 2021; 13(11):3761. doi:10.3390/nu13113761 10.3390/nu13113761 CASWeb of Science®Google Scholar 5Shridhar R, Blinn P, Huston J, Meredith KL. Outcomes of adjuvant radiation therapy after chemotherapy in resected extrahepatic cholangiocarcinoma: a National Cancer Database analysis. Cancer. 2023; 129(6): 890-900. doi:10.1002/cncr.34625 10.1002/cncr.34625 CASWeb of Science®Google Scholar 6Zlotta AR, Ballas LK, Niemierko A, et al. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol. 2023; 24(6): 669-681. doi:10.1016/s1470-2045(23)00170-5 10.1016/S1470-2045(23)00170-5 Web of Science®Google Scholar 7Chen GG, Woo PYM, Ng SCP, et al. Impact of metformin on immunological markers: implication in its anti-tumor mechanism. Pharmacol Ther. 2020; 213:107585. doi:10.1016/j.pharmthera.2020.107585 10.1016/j.pharmthera.2020.107585 CASWeb of Science®Google Scholar 8Ma R, Yi B, Riker AI, Xi Y. Metformin and cancer immunity. Acta Pharmacol Sin. 2020; 41(11): 1403-1409. doi:10.1038/s41401-020-00508-0 10.1038/s41401-020-00508-0 CASWeb of Science®Google Scholar 9Cortellini A, D'Alessio A, Cleary S, et al. Type 2 diabetes mellitus and efficacy outcomes from immune checkpoint blockade in patients with cancer. Clin Cancer Res. 2023; 29(14): 2714-2724. doi:10.1158/1078-0432.ccr-22-3116 10.1158/1078-0432.CCR-22-3116 CASPubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation